Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytochrome P450 CYP2D6.

C R Wolf1, G Smith

  • 1University of Dundee Biomedical Research Centre, ICRF Molecular Pharmacology Unit, Ninewells Hospital and Medical School, United Kingdom.

IARC Scientific Publications
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials.

Drug metabolism and disposition: the biological fate of chemicals·2019
Same author

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.

British journal of cancer·2015
Same author

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

British journal of cancer·2014
Same author

Immunodetection of proteins by Western blotting.

Methods in molecular biology (Clifton, N.J.)·2012
Same author

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.

British journal of cancer·2012
Same journal

North America.

IARC scientific publications·2016
Same journal

Central and South America.

IARC scientific publications·2016
Same journal

Africa.

IARC scientific publications·2016
Same journal

Data availability and presentation.

IARC scientific publications·2016
Same journal

Age standardization.

IARC scientific publications·2016
Same journal

Data processing.

IARC scientific publications·2016
See all related articles

Genetic variations in CYP2D6 (debrisoquine hydroxylase) significantly impact drug metabolism, leading to diverse clinical outcomes. Understanding these CYP2D6 gene polymorphisms is crucial for personalized medicine and predicting disease susceptibility.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Clinical Pharmacology

Background:

  • Cytochrome P450 2D6 (CYP2D6) genetic polymorphism causes significant interindividual variability in drug metabolism.
  • Most CYP2D6 substrates are small molecules interacting with an aspartic acid residue in the active site via a basic nitrogen.
  • Altered CYP2D6 expression has profound clinical consequences due to the wide range of drug targets.

Purpose of the Study:

  • To explore the impact of CYP2D6 genetic polymorphism on drug metabolism.
  • To highlight the clinical significance of interindividual variations in CYP2D6 activity.
  • To discuss methods for determining CYP2D6 activity and allele frequencies.

Main Methods:

  • Phenotyping methods using probe drugs to assess CYP2D6 activity.

Related Experiment Videos

  • Genotyping methods employing PCR-based techniques to identify CYP2D6 alleles.
  • Analysis of CYP2D6 allele frequencies across different racial populations.

    • Main Results:

    • CYP2D6 genetic variations lead to pronounced interindividual differences in the metabolism of numerous drugs.
    • Allele frequencies of CYP2D6 vary significantly among diverse populations, with specific genotypes being rare in certain ethnic groups.
    • Inherited CYP2D6 allelic variants are linked to altered susceptibility to diseases like Parkinson's and various cancers.

    Conclusions:

    • CYP2D6 genetic polymorphism is a key determinant of drug response and toxicity.
    • Understanding CYP2D6 variations is essential for optimizing drug therapy and predicting disease risk.
    • Population-specific allele frequencies necessitate tailored approaches in pharmacogenomic testing and clinical application.